Programmable amide bond formation using de novo ligases
In the authors' words
Amide bond formation is of central importance in the chemical industry, underpinning the synthesis of small bioactive molecules, macrocycles, peptides and their conjugates. Conventional methods of amide synthesis rely on stoichiometric coupling agents and costly protecting group manipulations. While biocatalysis can alleviate some of these challenges, enzymes typically operate across a narrow range of substrates and their adaptation to new coupling partners requires extensive engineering. Here we show that de novo amide ligases featuring a cysteine catalytic triad can be programmed computationally to operate across diverse substrate classes with high selectivity. We first designed complementary peptide ligases to selectively functionalise either the N-terminus or a single lysine residue of a polypeptide sequence containing 36 competing lysines. Crystal structures of both ligases show excellent agreement with the designs, with structural modelling suggesting that amidation outcompetes hydrolysis because the catalytically competent geometry forms only upon acceptor binding. We then extended our approach to the synthesis of small bioactive molecules by designing stereoselective ligases that mediate a key amide bonding forming step in the synthesis of the preventative HIV therapeutic lenacapavir. These results establish de novo enzyme design as a programmable platform for achieving selective amide bond formations across a wide range of molecular targets.
In plain words AI summary
The researchers created new enzymes called de novo amide ligases that can be programmed by computer to work with many different molecules. They first designed peptide ligases that could add molecules to either the N-terminus or one specific lysine in a protein with 36 lysines. Crystal structures matched the designs, and modelling suggests the reaction beats water breakdown because the active shape only forms when the acceptor binds. They then designed stereoselective ligases for a key step in making lenacapavir, an HIV prevention drug. The results show that designing enzymes from scratch can be a programmable platform for selective amide bond formation across many molecular targets.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Thursday, November 12. bioRxiv. Preprint, not yet peer-reviewed.